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Abstract
Introduction: Signals from the epidermal growth factor receptor (EGFR) have typically been considered to provide
catabolic activities in articular cartilage, and accordingly have been suggested to have a causal role in osteoarthritis
progression. The aim of this study was to determine in vivo roles for endogenous EGFR signal activation in articular
cartilage.
Methods: Transgenic mice with conditional, limb-targeted deletion of the endogenous intracellular EGFR inhibitor
Mig-6 were generated using CreLoxP (Mig-6-flox; Prx1Cre) recombination. Histology, histochemical staining and
immunohistochemistry were used to confirm activation of EGFR signaling in the articular cartilage and joints, and
to analyze phenotypic consequences of Mig-6 loss on articular cartilage morphology, proliferation, expression of
progenitor cell markers, presence of chondrocyte hypertrophy and degradation of articular cartilage matrix.
Results: The articular cartilage of Mig-6-conditional knockout (Mig-6-cko) mice was dramatically and significantly
thicker than normal articular cartilage at 6 and 12 weeks of age. Mig-6-cko articular cartilage contained a
population of chondrocytes in which EGFR signaling was activated, and which were three to four times more
proliferative than normal Mig-6-flox articular chondrocytes. These cells expressed high levels of the master
chondrogenic regulatory factor Sox9, as well as high levels of putative progenitor cell markers including superficial
zone protein (SZP), growth and differentiation factor-5 (GDF-5) and Notch1. Expression levels were also high for
activated b-catenin and the transforming growth factor beta (TGF-b) mediators phospho-Smad2/3 (pSmad2/3).
Anabolic effects of EGFR activation in articular cartilage were followed by catabolic events, including matrix
degradation, as determined by accumulation of aggrecan cleavage fragments, and onset of hypertrophy as
determined by type × collagen expression. By 16 weeks of age, the articular cartilage of Mig-6-cko knees was no
longer thickened and was degenerating.
Conclusions: These results demonstrate unexpected anabolic effects of EGFR signal activation in articular cartilage,
and suggest the hypothesis that these effects may promote the expansion and/or activity of an endogenous EGFR-
responsive cell population within the articular cartilage.
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Introduction
Because adult articular cartilage has limited intrinsic
regenerative capacity, damage to the tissue due to
trauma or long term use during aging is not naturally
repaired, causing osteoarthritis [1-3]. Current clinical
strategies for articular cartilage repair include cell-based
approaches [4], such as Autologous Chondrocyte
Implantation [5], in which donor or autologous adult
chondrocytes are placed into focal articular cartilage
defects; or microfracture [6], in which penetration of the
subchondral bone beneath the defect allows influx of
endogenous blood and bone marrow cells into the
region. A disadvantage of both of these approaches is
that the defects tend to be filled by fibrocartilage [7],
which lacks the durability of hyaline cartilage. This is
likely due to characteristics inherent in the repair cells,
which include the poor proliferative capacity of adult or
aged chondrocytes, and their tendency to de-differenti-
ate [8]; and the cellular heterogeneity of bone marrow,
which contains only a small percentage of progenitor
cells capable of chondrogenic differentiation [9,10].
Accordingly, critical steps towards articular cartilage
repair and osteoarthritis treatment will be to identify
progenitor cells with the ability to form articular carti-
lage, and to understand the signals that control their
proliferation and chondrogenic differentiation [11].
The superficial and/or middle zones of normal articular
cartilage have been identified as regions enriched in cells
which are highly proliferative and/or which express
mesenchymal or progenitor cell markers [12-17]. In vitro
differentiation assays have demonstrated the potential of
these cells to differentiate into the chondrogenic lineage
[12-18], and particularly, the permanent hyaline or
articular cartilage lineage [12,17,18]. Thus, these popula-
tions have been suggested to represent a reserve capacity
of the normal articular cartilage for homeostasis or
regeneration [14-16].
It is apparent that endogenous progenitors present
within the articular cartilage are inadequate for self-
repair, as they are observed in osteoarthritic cartilage
[14,15,17,19,20]. It has been suggested that advanced age,
which is typical of idiopathic osteoarthritis, may reduce
the size and/or alter the activity of the progenitor cell
pools [19,21,22]. Osteoarthritic cartilage exhibits quanti-
tative and qualitative differences in the expression of pro-
genitor markers compared to normal cartilage [19,20],
and cells expressing progenitor markers are markedly
more abundant in fetal and juvenile articular cartilage
than in articular cartilage from adult or elderly patients
[22,23]. Thus, while progenitor cells offer exciting poten-
tial for articular cartilage repair and osteoarthritis treat-
ment, there is a critical need to identify signals which
promote expansion and/or activity of endogenous pro-
genitor cell pools in the articular cartilage, and/or which
stimulate chondrogenic potential by putative exogenous
cartilage repair cells.
The epidermal growth factor receptor (EGFR) network
is emerging as an important signaling family in cartilage
development, homeostasis and disease [24-35]. EGFR sig-
nals typically suppress chondrogenic differentiation and/
or homeostasis. For example, in vitro studies show that
EGFR signals suppress initial chondrogenic differentia-
tion by limb mesenchymal cells [27,28], and also suppress
matrix synthesis and/or stimulate activity of matrix
degradative enzymes by articular chondrocytes [29-32].
EGFR signals also promote the de-differentiation of
articular chondrocytes in vitro towards fibrogenic cell
types [33-35]. Together these observations demonstrate
effects of EGFR signaling in suppression of articular car-
tilage homeostasis, and suggest that activation of EGFR
signaling may be a causal factor in osteoarthritis. Consis-
tent with this, EGFR signaling is increased in the articular
cartilage of osteoarthritic patients [32], and in rats follow-
ing experimental surgical osteoarthritis induction [36].
To better understand the function of EGFR signaling in
articular cartilage in vivo, in this study we have developed
a murine model in which activation of EGFR signaling is
targeted to the developing and adult limbs, including the
joints and articular cartilage, via limb mesoderm-targeted
conditional loss of Mig-6, an endogenous intracellular
inhibitor of EGFR signaling [37]. The articular cartilage of
the knee joints of Mig-6-cko mice undergoes progressive
osteoarthritis-like changes characterized by late-stage
articular cartilage degradation, which is unexpectedly pre-
ceded by dramatic thickening of the articular cartilage.
The articular cartilage of Mig-6-cko joints is thickest at six
weeks of age, and articular cartilage thickening is preceded
by pronounced EGFR signal activation, significantly
enhanced proliferation, and expanded expression of the
master chondrogenic regulatory factor Sox9 and other
markers of putative progenitor cells, which is observed
within presumptive articular cartilage as early as postnatal
Day 5. Our study demonstrates for the first time anabolic
effects in articular cartilage occurring in association with
EGFR signal activation, and suggests novel possibilities for




To produce Mig-6 conditional loss targeted to the meso-
derm of developing limb buds, the Prx1-Cre transgene,
which drives recombination in early limb bud mesench-
yme [38], was introduced into Mig-6-flox/flox mice [39].
Resultant Prx1-Cre;Mig-6-flox/+ male mice were mated
with Mig-6-flox/flox female mice to obtain Mig-6 condi-
tional knockout mice (Prx1-Cre; Mig-6-flox/flox). Mig-6-
flox/flox littermates were used as controls. Genotyping
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of the mice and embryos was by polymerase chain reac-
tion (PCR) using DNA prepared from tail biopsies. All
protocols for animal use were approved by the Animal
Care Committee of the University of Connecticut Health
Center, and were in accordance with NIH guidelines.
Histology and staining
Limbs were dissected from adult mice and immediately
fixed in 4% paraformaldehyde and processed for paraffin
embedding. Histological analysis was performed on 7-
μm sections. Safranin O staining of glycosaminoglycans
was performed by staining sections with Weigert’s Iron
Hematoxylin and 0.02% aqueous Fast Green, followed
by rinsing with 1% acetic acid and staining with 0.1%
aqueous Safranin O.
Immunohistochemistry
Immunohistochemical staining was performed as previously
described [40]. In brief, sections were de-paraffinized,
rehydrated and incubated with 3% hydrogen peroxide in
water for 15 minutes to quench endogenous peroxidases.
After blocking with 10% normal goat serum for rabbit anti-
bodies or M.O.M blocking serum (Vector Laboratories,
Burlingame, CA, USA) for mouse antibodies, the slides
were incubated with primary antibodies in blocking buffer
at 4°C overnight. Dilutions of primary antibodies were as
follows: rabbit anti-Mig-6, (Sigma, St. Louis, MO, USA),
1:200; rabbit anti-pEGFR (Y1092), (Abcam, Cambridge,
MA, USA), 1:250; rabbit anti-SZP (Novus Biologicals, Little-
ton, CO, USA), 1:100; rabbit anti-Ki67 (Abcam, Cambridge,
MA, USA), 1:50; rabbit anti-Notch1 (Abcam), rabbit 1:100;
rabbit anti-pSmad2/3 (R&D Systems, Minneapolis, MN,
USA), 1:100; anti-Sox9 (Abcam), 1:500; rabbit anti-Aggre-
can Neoepitope (Pierce, Rockford, IL, USA), 1:100; mouse
anti-collagen type × (Developmental Studies Hybridoma
Bank, Iowa City, IA, USA), 1:100; mouse anti-Activated-b-
Catenin (Millipore, Temecula, CA, USA), 1:100; goat
anti-GDF-5 (R&D Systems), 1:50. The slides were washed
with TBS containing 0.1% Tween 20 and then incubated
with 1:200 biotinylated goat anti-rabbit IgG (Vector Labora-
tories) or M.O.M. Biotinylated Anti-mouse Ig Reagent
(Vector Laboratories). After washing, the slides were
incubated with Vectastain Elite ABC Reagent (Vector
Laboratories) and developed with DAB reagent (Vector
Laboratories) followed by counterstaining with hematoxylin.
For negative controls, the specific antibody was omitted;
none showed a positive reaction.
In situ hybridization
The mouse Col10a1 probe (gift of B. Olsen, Harvard
University, Boston, MA) was subjected to digoxigenin-
labeling (Roche Molecular Biochemicals, Indianapolis,
IN, USA) using the protocol described by the manufac-
turer. In situ hybridization was performed on serially
sectioned tissue that had been fixed in 4% paraformalde-
hyde as previously described [40].
Cell proliferation
Proliferating cells were detected with rabbit anti-Ki67
(Abcam), 1:100. Cell proliferation was quantified using
image analysis within Photoshop CS4 Extended (Adobe
Systems Inc. San Jose, CA, USA in fixed areas of 20×
digital photographs of adult Mig-6-flox/flox and Mig-6-
cko mice articular cartilage. Ki67-labeled cells within the
fixed area were automatically selected by color range, and
the number of labeled cells was determined manually
using the image analysis ‘Count Tool’ within Photoshop.
Four to six sections of tibial articular cartilage were
examined from the knees of five different Mig-6-flox/flox
and Mig-6-cko mice for each time point.
Determination of articular cartilage thickness
Articular cartilage thickness was determined by measur-
ing the mean distance at its thickest point from the
articular cartilage surface to the subchondral bone in
Safranin-O stained sections. Images were taken at 40×
from representative non-overlapping fields of knees
from different Mig-6-flox/flox and Mig-6-cko mice (n =
5 each at 12 weeks; n = 6 each at 6 weeks).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software Inc., San Diego, USA, USA). For
direct comparisons Mann-Whitney U tests were used.
Results
Thickening of the articular cartilage of Mig-6-flox;
Prx1Cre knee joints
Histological analysis of the knee joints of Mig-6-flox;
Prx1Cre (Mig-6-cko) mice revealed dramatic thickening
of the articular cartilage (Figure 1). At 12 weeks, the
articular cartilage of the tibial surfaces of control Mig-6-
flox mice was on average 162 ± 15 μm thick (n = 5),
compared to the average thickness of the tibial articular
cartilage of Mig-6-flox;Prx1Cre mice, which was 266 ±
36 μm thick (n = 5, P <0.01, compare Figure 1C vs D
and see graph in Figure 1F). The articular cartilage of
the femoral surfaces of Mig-6-cko joints was also
increased (283 ± 19 μm thick for Mig-6-cko, n = 5,
compared to 132 ± 16 μm thick for control Mig-6-flox,
n = 5, P <0.01, data not shown). Histochemical staining
revealed that Safranin-O positive staining was reduced in
the superficial zone of the thickened Mig-6-cko articular
cartilage (compare Figure 1C, D). The superficial zone of
the articular cartilage of the Mig-6-cko joints was highly
cellular and contained numerous rounded chondrocytes
often appearing as doublets (Figure 1D). As shown in
Figure 1G and 1H, the articular cartilage of Mig-6-cko
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Figure 1 Articular cartilage thickness and Mig6 localization. (A-D) Sections of 12-week-old normal Mig-6-flox (A, C) and Mig-6-flox;Prx1Cre
conditional knockout (Mig-6-cko) knees (B, D) stained with Safranin-O to detect proteoglycan (red) and counterstained with Fast Green (tibia is
at the bottom, femur is at the top). The articular cartilage of the tibial and femoral surfaces (boxed areas in A, B, shown at high magnification in
C, D) is dramatically thickened in the Mig-6-cko knee (B, D). In addition, reduced Safranin-O staining is observed in the the superficial zone of the
Mig-6-cko articular cartilage (* in D), which is highly cellular and contains numerous rounded chondrocytes often appearing as doublets
(arrowheads in D). Note also the thickened ligaments (lg) and menisci (m); abundant connective tissue (ct), and thin subchondral bone (sb) in
Mig-6-cko knee joint (compare A to B). (E) Immunohistochemical detection of Mig-6 protein in 12-week-old normal Mig-6-flox tibial articular
cartilage, showing Mig-6-positive chondrocytes (brown stain, arrows) mainly in the superficial zone. Some Mig-6-positive chondrocytes were also
present in deeper zones (arrowhead) in the articular cartilage adjacent to the tidemark. (F) Measurement of the widths of the normal and Mig-6-
cko tibial articular cartilages (for example, see bars in C, D) shows that the Mig-6-cko articular cartilage is dramatically thicker than normal
articular cartilage. The articular cartilage of Mig-6-cko mice was more than 1.5-fold thicker than normal articular cartilage at 12 weeks of age
(P <0.01). (G, H) Sections of six-week normal Mig-6-flox (G) and Mig-6-cko knees (H) stained with Safranin-O/Fast Green. The articular cartilage of
Mig-6-cko joints is also dramatically thickened at six weeks of age (compare bars in G vs. H). (I) Measurement of the widths of the normal and
Mig-6-cko tibial articular cartilages shows that the Mig-6-cko articular cartilage is nearly two-fold thicker at six weeks of age (P <.001). Scale Bar =
500 μm (A, B); 200 μm (C, D); 100 μm (E, G, H).
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mice at 6 weeks was also dramatically thickened, and even
thicker than at 12 weeks (318 μM + 16.6 μm thick for
Mig-6-cko, n = 6, compared to 170 + 20.9 μm thick for
control Mig-6-flox, n = 6, P <0.001, see graph in Figure 1I).
To confirm endogenous expression of Mig-6 protein in
normal articular cartilage, immunohistochemical staining
with a Mig-6 antibody was performed, which demon-
strated Mig-6 protein localization particularly in the super-
ficial zone of the normal 12 week tibial (Figure 1E) and
femoral (not shown) knee articular cartilages. Isolated
Mig-6-positive chondrocytes were also located deep in the
articular cartilage adjacent to the tidemark (Figure 1E) and
in the subchondral bone (see Additional Figure 1A).
Mig-6-cko knee joints also contained thickened lateral
and central ligaments which stained intensely with
Safranin-O, abundant connective tissue, and enlarged
menisci (Figure 1B). The subchondral bone present in
the Mig-6-cko knee was thin and contained large bone
marrow sinuses (Figure 1B).
EGFR signaling in normal and Mig-6-flox;PrxCre articular
cartilage
Immunostaining with an antibody against the phosphory-
lated tyrosine residue 1092 of the EGFR kinase domain
showed that EGFR signaling was occurring in normal
articular cartilage, and increased in Mig-6-cko articular
cartilage (Figure 2). In normal control Mig-6-flox knees,
EGFR signaling was activated as early as postnatal Day 5
(the earliest day examined) in chondrocytes located in the
distal region of the tibial epiphysis which will form the
articular cartilage (Figure 2A). At six weeks of age EGFR
signaling in normal tibial articular cartilage was limited to
the superficial zone (Figure 2C). In the normal knee at
12 weeks of age, few superficial chondrocytes were EGFR-
positive, but EGFR-positive chondrocytes were relatively
abundant in the calcified zone adjacent to the chondro-
osseous junction, as well as in the subchondral bone itself
(Figure 2E). In Mig-6-cko knee articular cartilage, EGFR
signaling was dramatically enhanced in these regions
compared to controls (Figure 2B, D, F). In addition,
the domain of EGFR signal activation was expanded as
early as postnatal Day 5 (compare bars in Figure 2A vs.
Figure 2B), and EGFR-positive chondrocytes were abun-
dant in the middle region of the Mig-6-cko articular carti-
lage at 6 and 12 weeks, a region which in controls
contained few EGFR-positive chondrocytes (compare
Figure 2C, E to D, F). The patterns of EGFR activation
were similar in femoral articular cartilage (not shown).
Figure 2 EGFR signaling. Sections of the distal tibia of normal Mig-6-flox (A, C, E) and Mig-6-flox;Prx1Cre conditional knockout (Mig-6-cko) knees
(B, D, F) immunostained with a phospho-EGFR antibody (p-EGFR, brown) and counterstained with hematoxylin. At postnatal Day 5 (A, B), p-EGFR
signaling is occurring in the distal region of the tibial epiphysis (the presumptive articular cartilage) in both normal and Mig-6-cko knees, but
staining is more robust in the Mig-6-cko knee and the domain of EGFR signal activation is expanded (compare bars in A, B). At six weeks of age
(C, D), p-EGFR immunostaining in normal articular cartilage is limited to cells in the superficial zone (arrows in C), but in Mig-6-cko articular
cartilage staining is intense and abundantly localized in both superficial and middle regions (arrows and arrowheads, respectively, in D). At
12 weeks of age (E, F), p-EGFR-positive chondrocytes are only occasionally observed in the superficial and calcified zones of normal articular
cartilage (arrows and arrowheads in E); whereas p-EGFR-positive chondrocytes are present in superficial, middle and calcified zones of the Mig-6-
cko articular cartilage (arrows and arrowheads in F). Scale Bar = 50 μm (A-F).
Shepard et al. Arthritis Research & Therapy 2013, 15:R60
http://arthritis-research.com/content/15/3/R60
Page 5 of 16
Articular chondrocyte proliferation in normal and Mig-6-
flox;Prx1Cre knee joints
Cell proliferation, as determined by immunostaining with
a Ki67 antibody, was dramatically enhanced in the articu-
lar cartilage of Mig-6-cko knee joints compared to
control Mig-6-flox knee joints (Figure 3). In control Mig-
6-flox tibia, only scattered proliferating cells were present
in the presumptive articular cartilage at postnatal Day 5
(Figure 3A), and in the articular cartilage at 6 and 12
weeks of age (Figure 3C, E), and quantification of Ki67-
positive cells revealed that the level of proliferation
remained constant over time (Figure 3G). In contrast, in
Figure 3 Cell proliferation. (A-F) Sections of the tibial articular cartilage of normal Mig-6-flox (A, C, E) and Mig-6-flox;Prx1Cre conditional
knockout (Mig-6-cko) knees (B, D, F) immunostained with a Ki67 antibody (brown) and counterstained with hematoxylin. (A, C, E) Scattered
proliferating cells (arrows in A) are present in the presumptive articular cartilage of normal Mig-6-flox tibia at postnatal Day 5 (indicated by bars)
and in the superficial zones of normal Mig-6-flox tibial articular cartilage at 6 and 12 weeks (arrows in C, E), and rarely in the calcified zone
(arrowhead, E). However, in Mig-6-cko knees, abundant proliferating cells are located in these regions (arrows in B, D, F), and the domain of
robust proliferation is expanded as early as postnatal Day 5 (compare bars in A, B). In addition, proliferating cells are also detected in the middle
zone at six weeks (arrowheads in D). (G) Cell counting shows that proliferating cells present in normal articular cartilage (closed circles) remain at
a low and constant level from Day 5 to 12 weeks while proliferating cells present in Mig-6-cko articular cartilage (closed squares) are over three-
fold more abundant at postnatal Day 5 (P <0.01) and four-fold more abundant at 6 and 12 weeks of age (P <0.01). Scale Bar = 50 μm (A-F).
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the Mig-6-cko knee, abundant proliferating cells were
present in the presumptive articular cartilage at postnatal
Day 5, and in the superficial zones at 6 and 12 weeks,
and the domain of robust proliferation is expanded as
early as postnatal Day 5 (compare bars in Figure 3A vs.
Figure 3B). In addition, proliferating cells were also pre-
sent in deeper regions (Figure 3B, D, F). Cell counting
revealed that the number of proliferating cells was about
three times higher than controls at postnatal Day 5 (P <
0.01, n = 5, Figure 3G), and four times higher than con-
trols at 6 and 12 weeks of age (P <0.01, n = 5, Figure 3G).
EGFR signal activation, increased proliferation, and tis-
sue thickening were also observed in other regions of the
Mig-6-deficient knee joint at six weeks of age (see Addi-
tional Figures 1 and 2). These regions include the central
ligaments and especially the ligament/cartilage junctions
(Additional file 1, Figure S1), as well as the menisci and
synovium (see Additional file 2, Figure S2). Endogenous
Mig-6 immunostaining was present in these tissues in nor-
mal six-week Mig-6-flox joints, but was not detected in
any tissues including the articular cartilage, menisci, bone
or ligament of six-week old Mig-6-cko joints (see Addi-
tional Figures 1 and 2).
Expanded expression of progenitor cell markers in
Mig-6-flox;Prx1Cre articular cartilage
As shown by immunostaining, the relative abundance of
cells expressing Sox9, superficial zone protein (SZP),
growth and differentiation factor-5 (GDF-5), Notch1,
activated b-catenin, and the transforming growth factor
beta (TGF-b) mediators phospho-Smad2/3 (pSmad2/3),
was markedly increased in Mig-6-cko articular cartilage
compared to control articular cartilage (Figures 4 and 5).
At 12 weeks of age, cells expressing these markers were
present in the superficial zone of control Mig-6-flox tibial
articular cartilage (Figure 4A, C, E and Figure 5A, C, E).
However, in 12-week old Mig-6-cko tibial articular carti-
lage, cells expressing these markers were considerably
more abundant and were present not only in the superfi-
cial but also in the middle zones (Figure 4B, D, F and
Figure 5B, D, F). The distribution and relative abundance
of these markers in Mig-6-cko femoral cartilage was also
increased compared to control Mig-6-flox femoral articu-
lar cartilage (not shown). At six weeks of age, enhanced
expression and expanded distribution of Sox9, Notch1,
pSmad2/3 and SZP was also evident in Mig-6-cko articu-
lar cartilage (Figure 6H, J, L, N) compared to control
Mig-6-flox articular cartilage (Figure 6G, I, K, M). Nota-
bly, an increased abundance and expanded distribution
of cells expressing of Sox9, Notch1 and pSmad2/3 pro-
tein relative to controls was also detected in the
presumptive articular cartilage of Mig-6-cko at postnatal
Day 5, the earliest day examined (compare region shown
by bars in Mig-6-flox (Figure 6A, C, E) vs Mig-6-cko
(Figure 6B, D, F). Measurement of the length of the bars
indicates the region of expanded marker gene expression
in the Mig-6-cko is approximately 25% thicker than in
normal Mig-6-flox controls.
Matrix remodeling and chondrocyte hypertrophy in
Mig-6-flox;Prx1Cre articular cartilage
Little or no matrix turnover, as determined by immunos-
taining with an antibody to the aggrecan-cleavage frag-
ment NITEGE, was detected in normal Mig-6-flox tibial
articular cartilage at 6 and 12 weeks of age (Figure 7A-D).
Safranin-O staining in normal Mig-6-flox tibial articular
cartilage was also uniform at 6 and 12 weeks. In contrast,
Safranin-O staining was reduced in the superficial zone of
Mig-6-cko tibial articular cartilage, and this region con-
tained immunoreactive NITEGE cleavage fragments
(Figure 7E-H). The intensity of NITEGE immunostaining
at 6 weeks was low, and became considerably increased
by 12 weeks in Mig-6-cko articular cartilage (compare
Figure 7G to H). Little or no NITEGE-positive immunos-
taining was observed in either normal or Mig-6-deficient
presumptive articular cartilage at postnatal Day 5 (not
shown). Few hypertrophic chondrocytes, detected
through immunostaining for type × collagen and/or by
in situ hybridization with a type × collagen probe, were
observed in the articular cartilage of either normal Mig-
6-flox or Mig-6-cko knees at six weeks (Figure 7I-L).
However, at 12 weeks, while few hypertrophic chondro-
cytes were detected in normal Mig-6-flox knees, several
hypertrophic chondrocytes were observed in the articu-
lar cartilage of Mig-6-cko knees (compare Figure 7M, N
to Figure 7O, P).
Late stage degradation in Mig-6-flox;Prx1Cre articular
cartilage
At 16 weeks of age, Mig-6-cko articular cartilage was no
longer overtly thickened and degradation of the articular
cartilage along with gross joint abnormality was present
(Figure 8). The tibial articular cartilage of Mig-6-cko
knee joints at 16 weeks was comparable in thickness to
normal articular cartilage at that age (Figure 8), but was
reduced in thickness compared to Mig-6-cko articular
cartilage at 12 and 6 weeks of age (compare Figure 8D to
Figures 1D, H). In addition, the tibial articular cartilage
was discontinuous, with loss of integrity both at the sur-
face and at the chondro-osseous junction (Figure 8D).
In some regions of the joint, it was not possible to detect
a clear separation between the tibial articular cartilage
surface and the meniscal fibrous tissue that filled the
inter-articular space (Figure 8D). The knee joints of
16-week-old Mig-6-cko mice also contained fused and
highly chondrified central ligaments; thickened and fibro-
genic menisci; reduced subchondral bone area; and pro-
minent central and lateral osteophytes (Figure 8B).
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Discussion
As EGFR signals have typically been reported to have
negative roles in cartilage differentiation and homeosta-
sis [27-36], our observation that in vivo activation of
EGFR signaling leads to transient thickening of the
articular cartilage is unexpected, and suggests potential
novel anabolic functions for EGFR signals in cartilage
tissue. The articular cartilage thickening that accompa-
nies EGFR activation is also accompanied by increased
proliferation of cells within the articular cartilage. EGFR
signals have well-established mitogenic roles for many
progenitor cell types, including mesenchymal progeni-
tors [41,42], and our previous studies have shown that
EGFR signals stimulate in vitro and in vivo proliferation
by embryonic limb mesenchymal cells [27,43], and are
also required for in vivo proliferation of immature chon-
drocytes in developing limb skeletal elements [44].
As proliferation is a requirement for chondrogenic dif-
ferentiation by progenitor cells [45], our observation
that activation of EGFR signaling stimulates proliferation
in the articular cartilage, and especially in the superficial
layers, which are enriched in progenitor cells [13-17], is
consistent with an important role for endogenous EGFR
signals in providing these pro-proliferative cues.
Progenitor cell populations present in the articular carti-
lage have been identified based on their expression of cell
surface mesenchymal progenitor markers [14,15]; and/or
expression of Notch1, Sox9, superficial zone protein (SZP)
(aka prg4/lubricin), and growth and differentiation factor-
5 (GDF-5) [12,13,16-18,46], which have been implicated in
cartilage or articular cartilage lineage differentiation, and/
or maintenance of chondrogenic potential [16,18,46-48].
Although definitive markers for articular cartilage progeni-
tors are lacking [19], our observation that Mig-6-deficient
Figure 4 Localization of Sox9, SZP and GDF-5. Sections of the tibial articular cartilage of 12-week-old normal Mig-6-flox (A, C, E) and Mig-6-flox;
Prx1Cre conditional knockout (Mig-6-cko) knees (B, D, F) immunostained with antibodies against Sox9 (A, B); superficial zone protein (SZP, C, D);
and growth and differentiation factor-5 (GDF5, E, F). In normal articular cartilage, immunostaining is localized to cells mainly in the superficial zone
(arrows in A, C, E) while in Mig-6-cko articular cartilage, immunostaining is dramatically increased and positive cells are located not only in the
superficial zone but also in deeper zones (arrows in B, D, F). Scale Bar = 50 μm (A-D); 25 μM (E, F).
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articular cartilage contains a population of cells which are
highly proliferative and which express Notch1, Sox9, SZP
and GDF-5 suggests the existence of an endogenous
EGFR-responsive progenitor cell pool in articular cartilage.
These putative progenitor cells appear to have the poten-
tial to differentiate and contribute to the thickened Mig-6-
cko articular cartilage, as the chondroprogenitor marker
and master chondrogenic regulator, Sox9, is up-regulated
by the cells as they transition from the superficial zone
into deeper regions of the articular cartilage.
The EGFR-responsive putative progenitor cells we
observe in Mig-6-deficient articular cartilage also express
increased levels of the TGF-b mediators pSmad2/3, as well
as high levels of nuclear-localized activated b-catenin, sug-
gesting TGF-b and canonical Wnt signaling pathways are
stimulated in these cells. This is consistent with the pro-
posed roles for these pathways as key regulators of articu-
lar cartilage progenitor cell and/or articular chondrocyte
phenotypes [18,49]. For example, in vitro, articular carti-
lage superficial zone cells have been shown to proliferate
and express progenitor or superficial zone markers in
response to TGF-b1 [50] and to transient activation of
canonical Wnt signaling [18]; and in vivo, transient activa-
tion of b-catenin signaling, which like the EGFR has typi-
cally been associated with osteoarthritis [51] also causes
articular cartilage thickening in postnatal mice [52]. Intri-
guingly, synergistic interactions occur among the TGF-b,
Wnt and EGFR network in other systems [53-57]. The co-
localization of pSmad2/3 and activated b-catenin by cells
in the Mig-6-cko articular cartilage in which EGFR
Figure 5 Localization of Notch1, pSmad2/3 and active b-catenin. Sections of the tibial articular cartilage of 12-week normal Mig-6-flox
(A, C, E) and Mig-6-flox;Prx1Cre conditional knockout (Mig-6-cko) knees (B, D, F) immunostained with antibodies against Notch1 (A, B); the
TGFb1-mediators phosphorylated Smad2/3 (pSmad2/3) (C, D); and the canonical Wnt mediator activated b-catenin (E, F). In normal articular
cartilage, immunostaining is localized to occasional cells mainly limited to the superficial zone (arrows in A, C, E) while in Mig-6-cko articular
cartilage, immunostaining is intensified and positively-stained cells are located not only in the superficial zone but also in deeper zones (arrows in
B, D, F). Strong nuclear localization of active B-catenin is also observed in Mig-6-cko articular chondrocytes (arrowheads in F). Scale Bar = 50 μm
(A-D); 25 μM (E, F).
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Figure 6 Time-dependent expansion of marker gene expression. (A-F) Sections of the distal tibial epiphysis of normal Mig-6-flox (A, C, E)
and Mig-6-flox;Prx1Cre conditional knockout (Mig-6-cko) (B, D, F) at postnatal Day 5, immunostained with antibodies against Sox9 (A, B); Notch1
(C, D); or the TGFb1-mediators phosphorylated Smad2/3 (pSmad2/3) (E, F). Immunostaining in the presumptive articular cartilage of the normal
Mig-6-flox tibia is limited to a distal portion of the epiphyses (indicated by bars in A, C, E). However, immunostaining is intensified in the
presumptive articular cartilage of the Mig-6-cko tibia, and the region of immunostaining is expanded (compare bars in B, D, F to A, C, E). (G-N)
Sections of six-week old tibial articular cartilage of normal Mig-6-flox (G, I, K, M) and Mig-6-cko (H, J, L, N) joints immunostained with antibodies
against Sox9 (G, H); Notch1 (I, J); pSmad2/3 (K, L) or superficial zone protein (SZP, M, N). Enhanced marker expression by cells in the superficial
and middle zones is evident in the six-week-old Mig-6-cko articular cartilage compared to control Mig-6-flox articular cartilage (arrows).
Scale bar = 100 nm.
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signaling is also activated suggests that expansion or acti-
vation of putative progenitor cells within the articular car-
tilage may involve interactions between the EGFR network
and the TGF-b and canonical Wnt networks.
Mig-6 is an intracellular inhibitor of EGFR signaling [37]
which binds to the intracellular kinase domain of the EGFR
[58]. One of the roles of Mig-6 is as a tumor suppressor
gene [59], and in accordance with the well-established
Figure 7 Matrix remodeling and chondrocyte hypertrophy. (A-D) Sections of the tibial articular cartilage of 6-week-old (A, C) and 12-week-old (B,
D) normal Mig-6-flox knees stained with Safranin-O (A, B) or immunostained for NITEGE-positive aggrecan-cleavage fragments (NITEGE, C, D). The
normal articular cartilage stains uniformly for Safranin-O, and aggrecan cleavage fragments are not detected. (E-H) Sections of the tibial articular
cartilage of 6-week-old (E, G) and 12-week-old (F, H) Mig-6-flox;Prx1Cre (Mig-6-cko) knees stained with Safranin-O (E, F) or immunostained for NITEGE-
positive aggrecan-cleavage fragments (NITEGE, G, H). The superficial zone of Mig-6-cko knee articular cartilage stains weakly for Safranin-O (* in E, F)
and contains NITEGE-positive aggrecan cleavage fragments (arrows in G, H) which are more abundant at 12 weeks than at 6 weeks (compare H to G).
(I-L) Sections of the tibial articular cartilage (I, J) of six-week-old normal Mig-6-flox (I) and Mig-6-flox-cko (J) knees, immunostained with a collagen type
× antibody to identify hypertrophic chondrocytes. Only an occasional hypertrophic chondrocyte is detected in either normal or Mig-6-cko articular
cartilage at six weeks of age (arrows in I, J). As a positive control (K, L) note the robust collagen type × immunostaining in the hypertrophic
chondrocytes of both normal Mig-6-flox (K) and Mig-6-cko growth plates (arrowheads in K, L). (M-P) Sections of the tibial articular cartilage of 12-week-
old normal Mig-6-flox (M, N) and Mig-6-flox-cko (O, P) knees, immunostained with a collegen type × antibody (M, O) or subjected to in situ
hybridization for type × collagen mRNA (N, P). While few or no hypertrophic chondrocytes are detected in normal articular cartilage, several
hypertrophic chondrocytes are observed in Mig-6-cko articular cartilage (arrows in O, P). Scale Bar = 50 μm (A-H); 20 μm (I-P).
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involvement of EGFR signaling in oncogenic progression
[60], mice with global Mig-6 loss experience widespread
and precocious tumor development [61]. Thus, it has been
suggested that Mig-6 mediated inhibition of EGFR signals
has evolved to control potentially inappropriate prolifera-
tive responses following cellular injury or stress [59]. Nota-
bly, Mig-6 is up-regulated in response to mechanical stress
[62], and mice with global Mig-6 loss have previously been
reported to develop early-onset degenerative joint disease
in their load-bearing joints [26]. The reported knee joint
phenotype of mice with global Mig-6 loss is similar to what
we have observed in Mig-6-cko mice, including the pre-
sence of fibrous tissue and osteophytes within the joint, and
loss of proteoglycan staining and eventual degradation of
the articular cartilage [26]. The present study extends these
findings by revealing previously unsuspected anabolic
effects accompanying Mig-6 loss and EGFR signal activa-
tion in articular cartilage, and by suggesting the presence of
a putative progenitor cell population in the articular carti-
lage that is expanded in response to Mig-6 loss. Our obser-
vations suggest that release of Mig-6-mediated inhibition of
EGFR signaling in Mig-6-cko articular cartilage activates
EGFR-mediated anabolic responses by stimulating the pro-
liferation and expansion of what we suggest are progenitor
populations within the articular cartilage.
It is important to point out that as Mig-6 functions are
downstream of ligand activation of the EGFR, Mig-6 loss
does not result in constitutive or ligand-independent
EGFR activation, but rather represents de-repression
of endogenous ligand-bound receptor signals [37,58].
Figure 8 Late-stage articular cartilage degradation. Sections of 16-week normal Mig-6-flox (A, C) and Mig-6-flox;Prx1Cre conditional knockout
(Mig-6-cko) knees (B, D) stained with Safranin-O and counterstained with Fast Green (tibia is at the bottom, femur is at the top; boxed areas in
A, B are enlarged in C, D). At 16 weeks, the tibial articular cartilage of the Mig-6-cko knee is comparable in thickness to that of the normal knee
(bars in C, D) but is discontinuous, with loss of surface integrity (* in D) and fusion with the overlying fibrogenic meniscal tissue (m). In addition,
Mig-6-cko knee joints contain fused central ligaments which stain intensely with Safranin-O (lg in B), prominent osteophytes (op), and thin
subchondral bone (sb). Scale Bar = 100 μm.
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The endogenous expression of Mig-6 in chondrocytes,
mainly in the superficial zone of normal adult murine
articular cartilage, closely matches that of endogenous
EGFR signaling, and is consistent with activation of EGFR
signaling in this region following Mig-6 loss. As few Mig-
6-positive chondrocytes were detected outside the superfi-
cial zone in normal articular cartilage, it is possible that
the enhanced EGFR signal activation we observed in dee-
per regions of the Mig-6-cko articular cartilage is due to
release of Mig-6-inhibition by cells expressing Mig-6 near
or below the limit of immunohistochemical detection,
and/or is the result of proliferative expansion of the super-
ficial zone cells which originally expressed it. The three- to
four-fold increase in proliferative rate by superficial and
middle zone cells in Mig-6-cko articular cartilage is consis-
tent with this latter possibility.
The nature of the endogenous ligand-receptor interac-
tions mediating the EGFR responses we have observed
in Mig6-deficient articular cartilage is unknown. For
example, while the EGFR ligands transforming growth
factor alpha (TGF-a), and EGF are expressed by articu-
lar chondrocytes [32,63], studies typically implicate their
functions in catabolic effects of EGFR signaling asso-
ciated with osteoarthritic damage [29-32], rather than
the anabolic effects we have observed here. As distinct
EGFR signal outputs may be generated by differential
ligand activation [64], it is possible that anabolic EGFR
activities could be mediated by ligands other than EGF
or TGF-a; alternately, anabolic vs. catabolic EGFR activ-
ities in articular cartilage could be related to differences
in the timing or level of EGFR activation achieved in in
vitro studies vs. our in vivo studies. Choice of heterodi-
merization partner within the EGFR network can also
influence signal output [65], indicating additional invol-
vement from other EGFR-related receptors could also
occur. In addition, Mig-6 can directly bind to and inhibit
signal transduction by the EGFR-related receptor, ErbB2
[66]. Some EGFR-independent effects of Mig-6 have
been reported including direct inhibition of ERK [67]
and hepatocyte growth factor (HGF)/Met signaling [68];
however, HGF is not a potent regulator of anabolic or
catabolic gene expression in articular chondrocytes [69].
Our observation that EGFR signaling is dramatically
increased in Mig-6-cko articular cartilage in the same
regions where we observe major phenotypic effects is
consistent with a potentially primary role for the EGFR
in mediating most, if not all, of the articular cartilage
responses we have observed.
The catabolic effects of EGFR signaling in mature
articular chondrocytes in vitro include de-differentiation
towards fibrogenic cell types [33-35]. Conceivably then,
a possible explanation for the thickening of the Mig-6-
cko articular cartilage could be that EGFR signal activa-
tion results in de-differentiation and proliferation of
mature articular chondrocytes. However, we favor a
view that articular cartilage thickening in Mig-6-cko
mice results from stimulation of an endogenous pro-
genitor cell response, rather than a de-differentiative
response by mature cells. In support of this view are our
observations that enhanced EGFR signal activation,
increased proliferation, and expanded expression of pro-
genitor cell markers, occur as early as postnatal Day 5,
at which stage the articular cartilage is not morphologi-
cally distinct and is considered immature. Indeed, at
postnatal Day 5, the presumptive articular cartilage con-
sists only of a superficial layer, and the middle and dee-
per zones are not yet formed [70]. Thus, we believe it is
very likely that the time-dependent thickening of Mig-6-
cko articular cartilage is due to expansion and prolifera-
tion of an endogenous EGFR-responsive progenitor
population present in the articular cartilage and espe-
cially the superficial zone. If true, this would suggest
previously unsuspected activities for EGFR signaling in
promoting progenitor cell responses in articular carti-
lage, which could have important potential utility for
cartilage repair and regenerative medicine.
Ultimately, catabolic effects of sustained EGFR activation
in Mig-6-cko articular cartilage predominate over anabolic
ones, eventually causing thinning, loss of integrity and
degradation of the articular cartilage. One possible expla-
nation for these degenerative changes is that the immature
cartilage matrix present in the articular cartilage surface
layer may be insufficient to withstand cumulative loading
to the joints. It is also possible that the increased matrix
enzyme activity in Mig-6-cko articular cartilage we have
observed eventually outpaces deposition of new matrix by
the EGFR-responsive progenitor-derived cells. Indeed, sus-
tained matrix degradation is considered to be a turning
point in osteoarthritic progression leading to irreversible
cartilage damage [71]. Consistent with this possibility,
high-level activation of matrix enzymes occurs in the Mig-
6-cko articular cartilage at 12 weeks, shortly before overt
degradation and thinning of the articular cartilage. Activa-
tion of chondrocyte hypertrophy in the articular cartilage
is also considered to be part of the disease pathology lead-
ing to articular cartilage degeneration [72]. Consistent
with this, hypertrophic chondrocytes are observed in Mig-
6-cko articular cartilage, but not in normal Mig-6-flox
articular cartilage, at 12 weeks of age, shortly before overt
degradation of the articular cartilage occurs. These obser-
vations suggest the hypothesis that EGFR signal activation
has dual effects in articular cartilage, including an initial
anabolic stimulation mediated by expansion of progenitor
cells, which is followed by inappropriate activation of
matrix remodeling and chondrocyte hypertrophy, leading
to articular cartilage degradation and overt joint disease.
It is important to point out that at six weeks of age, which
is when the Mig-6-cko articular cartilage is thickest, and
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proliferation is greatest, hypertrophic chondrocytes are not
yet detected. This suggests that anabolic effects of EGFR
signal activation precede catabolic ones, and are not neces-
sarily coincident. Accordingly, an intriguing consideration
is the possibility that transient activation of EGFR signal-
ing might result in stimulation of anabolic activities, per-
haps without catabolic ones, which could suggest novel
future utility for EGFR signal activation in strategies for
articular cartilage repair and osteoarthritis treatment.
Additional studies are needed to clarify whether anabolic
effects resulting from EGFR activation can result in forma-
tion of functional articular cartilage tissue.
Conclusions
Our study provides in vivo evidence for the involvement
of EGFR signal activation in regulating potentially dis-
tinct anabolic and catabolic activities in articular carti-
lage, and demonstrates that the intracellular inhibitor
Mig-6 normally functions to limit these activities.
Release of Mig-6-mediated inhibition of EGFR signals
leads to an initial, transient, thickening of the articular
cartilage accompanied by proliferation and expansion of
an EGFR-responsive cell population, which expresses
high levels of the master chondrogenic regulatory factor
Sox9, as well as high levels of other putative progenitor
markers. In the presence of sustained EGFR activation,
these anabolic effects are followed subsequently by
accelerated catabolic effects (matrix degradation and
hypertrophy) which may contribute to the eventual loss
of the articular cartilage in this model.
Additional material
Additional Figure 1: Mig6 expression, EGFR activation and
proliferation in ligament and bone. Sections of the center of normal
six-week old Mig-6-flox knees (A, C, E) and Mig-6-flox;Prx1Cre conditional
knockout (Mig-6-cko) knees (B, D, F) immunostained with antibodies
against Mig-6 (A, B); phosphorylated EGFR (p-EGFR, C, D); or Ki67 (E, F). (A,
B) Endogenous localization of Mig-6 protein in ligament (arrows in A)
and bone (arrowheads in A) which is absent in the knockout animal (B).
(C-F) EGFR signaling and proliferation are occurring within the ligament
especially the ligament/cartilage junction (arrows), and within the
subchondral bone (arrowheads), of the normal Mig-6-flox knee (C, E), and
EGFR signaling and proliferation are increased in these tissues in the Mig-
6-cko knee (compare D, F to C, E). Scale Bar = 100 μm.
Additional Figure 2: Mig6 expression, EGFR activation and
proliferation in menisci and/or synovium. Sections of the menisci of
normal six-week-old Mig-6-flox knees (A, C, E) and Mig-6-flox;Prx1Cre
conditional knockout (Mig-6-cko) knees (B, D, F) immunostained with
antibodies against Mig-6 (A, B); phosphorylated EGFR (p-EGFR, C, D); or Ki67
(E, F). (A, B) Endogenous localization of Mig-6 protein in the superficial
region of the meniscus (arrowheads in A) which is absent in the knockout
animal (B). (C-F) EGFR signaling and proliferation are occurring within the
superficial region of the meniscus (arrowheads) of the normal Mig-6-flox
knee (C, E), and EGFR signaling and proliferation is enhanced and extends
further into the meniscus in the Mig-6-cko knee (compare D, F to C, E). In
addition, immunostaining for pEGFR is also present in the thickened Mig-6-
cko synovial tissue (arrow in D). Scale Bar = 100 μm.
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